Unintended consequences: the potential impacts of the British Association for Sexual Health and HIV (BASHH) 2019 gonorrhoea guidelines

Int J STD AIDS. 2021 Mar;32(4):344-351. doi: 10.1177/0956462420967575. Epub 2020 Dec 20.

Abstract

In 2019 the British Association for Sexual Health and HIV (BASHH) guidelines for the management of gonorrhoea were updated. Epidemiological treatment was reserved for sexual contacts presenting within 14 days of exposure only. The aim of this evaluation was to review the potential implications of the new guidelines on the management of gonorrhoea contacts. For this retrospective service evaluation, all gonorrhoea contacts presenting to two UK sexual health services in 2018 were identified using the Genitourinary Medicine Clinic Activity Dataset (GUMCAD) code Partner notification: gonorrhoea contact (PNG). Demographics, clinical characteristics and outcome data were collected from the electronic patient records. The 2019 guidelines were retrospectively applied to evaluate impact. For 436 patients seen as gonorrhoea contacts, gonorrhoea prevalence was 36% (159/436), and chlamydia prevalence 19% (83/429). Gonorrhoea prevalence varied with sexual risk: women 57% (61/107), heterosexual men 20% (28/143), men who have sex with men (MSM) 38% (69/183, p < .001); and with time since exposure: prevalence 43% (114/267) in those presenting within 14 days, 28% (42/149) after 14 days (p = .003). Epidemiological treatment of contacts presenting within 14 days would result in the treatment of 73% (114/156) of confirmed cases, with 37% (153/416) contacts unnecessarily treated. The BASHH gonorrhoea guideline changes represent an opportunity to improve antibiotic stewardship by reducing unnecessary treatment of gonorrhoea negative contacts.

Keywords: Europe; Gonorrhea (Neisseria gonorrhoeae); antibiotic; screening; sexual behaviour.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Disease Management
  • Female
  • Gonorrhea* / diagnosis
  • Gonorrhea* / drug therapy
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Humans
  • Male
  • Neisseria gonorrhoeae
  • Practice Guidelines as Topic*
  • Prevalence
  • Retrospective Studies
  • Sexual Health*

Substances

  • Anti-Bacterial Agents